Drug Information

Drug General Information
Drug ID
D0K5UF
Former ID
DIB019609
Drug Name
compound 8e
Drug Type
Small molecular drug
Indication Discovery agent Investigative [532627]
Formula
C22H23FN6O3S
InChI
InChI=1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1
InChIKey
DIXMBHMNEHPFCX-MCMMXHMISA-N
PubChem Compound ID
72710568
PubChem Substance ID
172112844, 194168292, 194946681, 211033273, 242083705, 249565817
Target and Pathway
Target(s) fer (fps/fes related) tyrosine kinase Target Info Inhibitor [532627]
ALK tyrosine kinase receptor Target Info Inhibitor [532627]
leukocyte receptor tyrosine kinase Target Info Inhibitor [532627]
BDNF/NT-3 growth factors receptor Target Info Inhibitor [532627]
FES proto-oncogene, tyrosine kinase Target Info Inhibitor [532627]
ROS1 Target Info Inhibitor [532627]
KEGG Pathway Non-small cell lung cancerhsa04010:MAPK signaling pathway
Neurotrophin signaling pathway
Alcoholism
Pathway Interaction Database SHP2 signaling
Posttranslational regulation of adherens junction stability and dissassembly
Neurotrophic factor-mediated Trk receptor signaling
Reactome NGF-independant TRKA activation
WikiPathways Differentiation PathwayWP706:SIDS Susceptibility Pathways
BDNF signaling pathwayWP2431:Spinal Cord Injury
References
Ref 532627Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.
Ref 532627Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.